News

Drug Therapy Combo May Have Led to Toxic Epidermal Necrolysis in Multiple Myeloma Patient

Multiple myeloma patients taking the immunomodulatory drug thalidomide may develop a potentially life-threatening dermatologic disorder called toxic epidermal necrolysis (TEN), according to a recent case report published in the International Journal of Dermatology. The study, “Toxic epidermal necrolysis induced by thalidomide and dexamethasone treatment for…

Oral 3-Drug Combo Looks Promising in Treatment-Resistant Myeloma

Combining three well-known oral drugs shows potential for heavily pretreated multiple myeloma patients who have grown resistant to therapy with one of the included drugs, according to the results of a study. The trio — low-dose Cytoxan (cyclophosphamide), Revlimid (lenalidomide) and prednisone (also known as Deltasone, among other brands) — was…

Kyprolis Combo Seen to Improve Life Quality in Relapsed Multiple Myeloma Patients

Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard two-drug regimen of Revlimid (lenalidomide) and dexamethasone significantly improves health-related quality of life in relapsed multiple myeloma patients, according to a secondary analysis of the ASPIRE clinical trial. These findings, published in the Journal of Clinical Oncology, further support the…

Phase 3 Trial Will Assess Darzalex-containing Combo Therapy in Multiple Myeloma Patients

The anti-CD38 agent Darzalex (daratumumab) will be investigated in a Phase 3 clinical trial in combination with Kyprolis (carfilzomib) and Decadron (dexamethasone) in relapsed/refractory multiple myeloma patients. The study will be conducted under a collaboration and supply agreement between Genmab, Janssen Biotech, and Onyx Pharmaceuticals (a subsidiary of…